



Overview and Path for Growth
Aurigene Strategic Collaboration

21 January, 2015

NASDAQ: CRIS

Forward Looking Statements



This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements about our business, plans, prospects and strategies and our expectations regarding our collaboration agreement with Aurigene, including our goals with respect to the PDL-1 and IRAK4 programs. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. There can be no guarantee that the Collaboration Agreement will continue for its full term, that we or Aurigene will maintain the financial resources necessary to continue financing our respective portion of research, development and commercialization costs or that we or Aurigene will successfully discover, develop or commercialize drug candidates under the collaboration. Our expectations could also be affected by risks and uncertainties relating to a failure of Curis or Aurigene to fully perform under the Collaboration Agreement and/or any early termination of the Collaboration Agreement, adverse results of clinical trials and preclinical studies that are the subject of the collaboration. We may also experience adverse results, delays and/or failures in our other drug development programs, including CUDC-907 and CUDC-427. We face risks and uncertainties relating to the successful commercialization of Erivedge® (vismodegib), which is currently being commercialized and sold by Genentech Inc. and F. Hoffmann-La Roche Ltd under our collaboration with Genentech. We also face risks relating to our wholly-owned subsidiary's Erivedge royalty-collateralized loan transaction, including the risk that it may not receive sufficient levels of royalty revenue from sales of Erivedge to satisfy the debt obligation or may otherwise lose its rights to royalties and royalty-related payments as a result of a foreclosure of the loan. We also face other important risks relating to our business, operations, financial condition and future prospects that are discussed in our Quarterly Report on Form 10-Q for the period ended September 30, 2014 and other filings that we periodically makes with the Securities and Exchange Commission.

The forward-looking statements included in this presentation represent our views as of the date of this Form 8-K. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of the attached presentation.

To become a leading biotech company that effectively develops and commercializes oncology drugs for significant patient benefit and access

- **New pipeline of Immuno-oncology drug candidates: exclusive, multi-year partnership with Aurigene**
 - PD-L1, orally available small molecule antagonist: IND filing expected in 2015
 - Multiple other immune checkpoint pathways: candidate antagonists under optimization
- **Precision drug candidates to address hematologic cancers**
 - CUDC-907: Phase 1, active in diffuse large B cell lymphoma. Phase 2 expected in 2015
 - IRAK4, orally available small molecule antagonist : IND filing expected in 2015
 - CUDC-427: Phase 1, focusing clinical studies in lymphoma (DLBCL, MALT)
 - CUDC-305 (Debio 0932): expect Phase 2 trial in systemic mastocytosis in 2015
- **Erivedge[®] for basal cell carcinoma – Roche/Genentech**
 - Approved in over 50 countries, royalty revenues to Curis

❑ Incorporated in 2002

- Operations in Bangalore and Hyderabad, India; Kuala Lumpur, Malaysia
- Current management and scientific teams joined since 2005
- Over 500 employees
- Independent subsidiary of Dr. Reddy's Laboratories

❑ Collaboration and proprietary discovery business

- Profitable business centered on integrated discovery expertise
 - Research, discovery, chemistry and preclinical development in multiple target classes
 - Collaborations with 6 of top 10 US and EU Pharma companies
 - Collaborations with multiple US and EU mid- and small biotech companies
 - Managed over 12 partnerships, and 22 simultaneous programs at peak
 - Over 60 discovery programs resulting in over 100 patents in last 8 years
 - Eight INDs filed, multiple programs in Phase 1 and Phase 2
- Focused on oncology and inflammatory disease

Curis – Aurigene Partnership Structure



Breakthrough strategic partnership in oncology drug discovery, development and commercialization

□ Aligned interests and complimentary expertise

- Seeking corporate transformation and growth through innovative medicines
- Aurigene discovery engine: research, discovery, chemistry and preclinical development
 - Expert, state-of the art, sizeable and cost effective
- Curis: translational medicine, regulatory, clinical development and commercialization
 - Experienced, focused and well networked

□ Multi-year, exclusive partnership

- Up to 5 years of broad exclusivity in collaboration scope
 - Immuno-oncology: immune-modulating molecular targets
 - Precision oncology: selected targets that are genetically altered in human cancers

□ Option and license agreement structure

- Curis option to license programs at development candidate stage
- Royalty-bearing, WW exclusive license (ex. India/ Russia) to compounds in programs

Curis – Aurigene Transaction Economics



- **Upfront equity grant**
 - 17.1M shares (19.9% of outstanding CRIS stock prior to the transaction)
 - Lock-up arrangement with 25% release every 6 months: 2-year total period
- **Research, option exercise and milestone payments**
 - Initial four programs: up to \$52.5M for first two, and up to \$50M for next two programs
 - All programs thereafter: up to \$140 million
- **Royalty rate on net sales by Curis: tiered from high single digit to 10%**
- **Sublicensing revenue sharing**
 - US/EU non-royalty and royalty payment sharing: declining percentage based on stage of development at sublicensing
 - Asia: 50% sharing of all revenues
- **Exclusivity option payments**
 - Annual payments after first two years of collaboration

Immune Checkpoint Pathways and Cancer Therapy


□ Immune regulatory pathways – active in tumor microenvironment

- Immune checkpoint proteins present on key cell types
 - Tumor cells
 - Dendritic cells and macrophages
 - Effector and regulatory T cells
 - Myeloid-derived suppressor cells (MDSCs)

- Antibodies targeting PD1/PD-L1 immune checkpoint pathway provide significant clinical benefit for certain cancer patients
- Antibodies targeting additional checkpoint pathway inhibitors in development

□ Curis-Aurigene strategy

- Address immune checkpoint pathways including PD1/PD-L1 using small molecule antagonists



Curis – Aurigene Collaboration

Scope and Focus



□ **Immuno-oncology**

- Small molecule antagonists of immune checkpoint pathways
- PD-L1 antagonists near development candidate stage
 - Aurigene to initiate IND-enabling studies including GLP toxicology
 - IND filing expected in 2H 2015
- Multiple additional programs ongoing that target other immune checkpoint pathways
- Potential for monotherapy or combination treatment strategies
 - Combination between multiple immune checkpoint pathway antagonists
 - Combination with other immuno-modulatory drugs or drug candidates
 - Combination with targeted agents, including Curis proprietary drug candidates



□ **Unique advantages of small molecule strategy**

- Differentiated PK: potential for better safety profile and improved tumor/tissue distribution
- Administration flexibility: convenient dosing, ease of combination therapy
- Efficient development: ability to examine drug candidates in preclinical models
- Cost of goods: may become significant advantage in combination therapy strategies

Lead PD-L1 Small Molecule Antagonist


Small molecule antagonist properties

- Induces proliferation of T-cells and IFN-gamma production in culture
- Clean off-target profile (enzyme, receptors, ion channels, kinases)
- Orally bioavailable with good PK properties
- Clean preliminary *in vivo* safety profile
- Induces INF-gamma production *in vivo* – similar to anti-mouse PD1 antibodies
- Inhibits syngeneic tumor growth *in vivo* – similar to anti-mouse PD1 antibodies



IRAK4 Inhibition for Cancer Therapy

- **Toll and IL-1 receptor signaling pathway**
 - MYD88 adaptor protein transduces receptor signaling to IRAK4
 - IRAK4 kinase activity, through IRAK1 is critical for NF- κ B activation
- **Activating MyD88 Mutations in human cancer**
 - 37% in ABC-DLBCL, 91% in Waldenstrom's, 10% in CLL




Lead IRAK4 Small Molecule Inhibitor


□ Small molecule inhibitor properties

- Inhibits IRAK4: biochemical $IC_{50} = 6nM$
- Excellent selectivity profile across 320 kinase panel
- Inhibits IRAK1 phosphorylation in cell-based assays: $IC_{50} \sim 150nM$
- Orally bioavailable with excellent PK properties – drug-like molecule
- Effective *in vivo* anti-tumor activity: 188% TGI in DLBCL tumor model (MYD88 mutation)
- Active in *in vivo* inflammatory disease models

Mechanistic Cell-based Activity



In vivo Anti-tumor Activity



Curis-Aurigene Collaboration Summary



- **Strategic collaboration to effect significant growth**
- **Aligned interests and incentives**
- **Novel technology generating pipeline in the most promising cancer therapy fields**
- **Alignment of complimentary expertise**
- **Considerable resources (competitive) with cost-effective teams**
- **Focused on multiple products and commercialization**
- **Risk and reward sharing with financial prudence**
- **Proximity to clinical proof-of-concept**
- **Consistent with innovative and rapid/efficient drug development (Biotech + Biotech)**

The logo features a stylized white eye icon above the word "CURIS" in a white serif font. A small "TM" trademark symbol is positioned to the right of the word.

CURIS™

